Second half of Zealand Pharma's congenital hyperinsulinism study data revealed at conference
The biotech company has now presented all top-line data from a two-part phase III study, demonstrating that dasiglucagon can reduce the duration of low blood sugar episodes.
by christian bundgaard, translated by daniel pedersen
Zealand Pharma’s dasiglucagon, a glucagon analog designed treat congenital hyperinsulinism, CHI, has demonstrated a statistical significant reduction in the duration of low blood sugar episodes known as hypoglycemia that characterize the disease, the company reveals in an announcement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
